Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating human disease.

Mammoth Biosciences, Inc., a biotechnology company harnessing its proprietary next-generation CRISPR gene editing platform to create potential one-time curative therapies, today announced new ...

Australian researchers have successfully introduced an improved version of Cas12a gene-editing enzyme in mice.

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modelling and interrogating human disease.A novel ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modelling and interrogating human disease.

Results prove that inversions can be generated in plants without causing further unwanted changes in the expression of genetic information.

It’s a new way to create “bi-paternal” mice that can survive to adulthood—but human applications are still a long way off.

Fintel reports that on January 27, 2025, Morgan Stanley downgraded their outlook for Intellia Therapeutics (NasdaqGM:NTLA) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 449.14% ...

Innovative synthetic biology techniques are revolutionizing microbiota-based therapies, enhancing microbial functions for ...

This new tool, known as minimal, versatile genetic perturbation technology (mvGPT), combines the powers of gene editing, ...

Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.